Arvinas develops protein degrader medicines that aim to remove disease-causing proteins to treat cancer and neurological diseases. ARVN reports earnings on Tue, Nov 3, 2026. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 10 | Evercore ISI Group | Maintained | Buy | |
| Aug 5 | Wells Fargo | Downgrade | Hold | |
| Aug 5 | Wedbush | Maintained | Hold | |
| Aug 4 | BTIG | Reiterated | Buy | |
| Jun 3 | Stephens & Co. | Reiterated | Buy |
Seasonality
How ARVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in ARVN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARVN is in one of them and how their past ARVN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ARVN in an article yet. Here's the latest on the wider market.
About Arvinas
Arvinas is a biotechnology company based in New Haven, Connecticut. It develops medicines that use targeted protein degradation, a method that removes disease-causing proteins from cells by using the body's own protein disposal system. Its drug candidates focus mainly on cancer and neurological diseases such as Parkinson's disease, and several are in clinical trials with patients. The company also works with larger drug makers, including Pfizer and Genentech, on early-stage research.
- Headquarters
- New Haven, CT
- Founded
- 2013
- Website
- arvinas.com ↗